Primary Care Diabetes
Volume 1, Issue 4 , Pages 209-211, December 2007

New treatments for type 2 diabetes—The DPP4 inhibitors

  • Roger Gadsby

      Affiliations

    • Corresponding Author InformationTel.: +44 2476 573101; fax: +44 2476 573959.

Warwick Medical school, University of Warwick, Institute of Education, Gibbet Hill Road Coventry, Warwickshire CV4 7AL, United Kingdom

Received 14 October 2007; accepted 15 October 2007. published online 03 December 2007.

Abstract 

Sitagliptin (brand name Januvia) the first of a new class of oral agents, the DPP4 inhibitors, which lower blood glucose in type 2 diabetes has recently been launched in UK. Another DPP4 inhibitor vildagliptin is due to be launched soon, and there are several others in the pipeline. This article gives an overview of this new class of medications.

Keywords: DPP4 inhibitors, Incretins, Type 2 diabetes

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1751-9918(07)00111-8

doi:10.1016/j.pcd.2007.10.004

Primary Care Diabetes
Volume 1, Issue 4 , Pages 209-211, December 2007

Article Tools